Market Overview

Vical to Report Allovectin Phase 3 Results Prior Open of Trade Monday; Hold Conference Call at 8:00 AM ET


Vical Incorporated (NASDAQ: VICL) today announced that the company will report top-line results from the Phase 3 Allovectin® Immunotherapy for Metastatic Melanoma (AIMM) trial before the opening of trading on Monday, August 12, and conduct a conference call and webcast to discuss the results at 8:00 a.m. Eastern Time on Monday, August 12. The call is open on a listen-only basis to any interested parties.

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (VICL)

View Comments and Join the Discussion!

Partner Center